Metabolic Profiling Revealed Prediction Biomarkers for Infantile Hemangioma in Umbilical Cord Blood Sera: A Prospective Study

• Published in: Journal of proteome research Vol. 21; no. 3; pp. 822 - 832
• Main Authors: Jiang, Cheng-Hong, Lin, Peng-Fei, Chen, Fa-Chun, Chen, Jia-Yao, Xie, Wen-Jun, Li, Ming, Hu, Xiao-Jie, Chen, Wen-Lian, Cheng, Yu, Lin, Xiao-xi
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 04.03.2022
• Subjects: prediction biomarker; umbilical cord blood serum; infantile hemangioma; metabolic profiling
• ISSN: 1535-3893; 1535-3907
• DOI: 10.1021/acs.jproteome.1c00430

Infantile hemangioma (IH), the most common benign tumor in infancy, mostly arises and has rapid growth before 3 months of age. Because irreversible skin changes occur in the early proliferative stage, early medical treatment is essential to reduce the permanent sequelae caused by IH. Yet there are still no early screening biomarkers for IH before its visible emergence. This study aimed to explore prediction biomarkers using noninvasive umbilical cord blood (UCB). A prospective study of the metabolic profiling approach was performed on UCB sera from 28 infants with IH and 132 matched healthy controls from a UCB population comprising over 1500 infants (PeptideAtlas: PASS01675) using liquid chromatography–mass spectrometry. The metabolic profiling results exhibited the characteristic metabolic aberrance of IH. Machine learning suggested a panel of biomarkers to predict the occurrence of IH, with the area under curve (AUC) values in the receiver operating characteristic analysis all >0.943. Phenylacetic acid had potential to predict infants with large IH (diameter >2 cm) from those with small IH (diameter <2 cm), with an AUC of 0.756. The novel biomarkers in noninvasive UCB sera for predicting IH before its emergence might lead to a revolutionary clinical utility.